Dr. Helena Yu, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
18 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR positive
EGFR
2Non-Small Cell Lung Cancer
Stage IV
EGFR positive
Stage III
Affiliated Hospitals
Clinical Trials Helena Yu, MD is currently running
BDTX-1535 + Temozolomide
for Glioblastoma and Lung Cancer
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.
Recruiting1 award Phase 1 & 214 criteria
Osimertinib + Chemotherapy
for Lung Cancer
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Recruiting1 award Phase 29 criteria
More about Helena Yu, MD
Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Helena Yu, MD has experience with
- Osimertinib
- Carboplatin
- Pemetrexed
- Etoposide
- Platinum
- Amivantamab
Breakdown of trials Helena Yu, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Thyroid Cancer
EGFR Gene Mutation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Helena Yu, MD specialize in?
Helena Yu, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Helena Yu, MD currently recruiting for clinical trials?
Yes, Helena Yu, MD is currently recruiting for 5 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Helena Yu, MD has studied deeply?
Yes, Helena Yu, MD has studied treatments such as Osimertinib, Carboplatin, Pemetrexed.
What is the best way to schedule an appointment with Helena Yu, MD?
Apply for one of the trials that Helena Yu, MD is conducting.
What is the office address of Helena Yu, MD?
The office of Helena Yu, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.